R&D Partner Content Welcome to the 5th TIL Therapies Summit! Advance Modified TIL Therapies, Optimize TIL Characterization, Gene Engineering & Streamline Manufacturing
R&D Partner Content 2nd Process Development for Cell Therapies The 2nd Process Development for Cell Therapies Summit Returns to Boston June 20-22
R&D Partner Content 5th Exosome Based Therapeutic Development Summit Uniting Key Biopharma and Academics Dedicated to Successfully Developing Exosome-Based Therapeutics
R&D Partner Content 6th Targeted Protein Degradation Summit Spearheading Degrader Therapeutics Towards the First Approval
R&D Partner Content 2nd Oligonucleotides CMC & Analytical Development Summit 202... Accelerate Oligonucleotide Approval with Tightened QC & Quality
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.